What is the maximum daily dose of Jardiance (Empagliflozin)?

From the Guidelines

The maximum daily dose of Jardiance (empagliflozin) is 25 mg taken once daily. This is based on the most recent and highest quality study available, which provides guidelines for the management of diabetic kidney disease and recommends a maximum daily dose of 25 mg for empagliflozin 1. Treatment typically starts with 10 mg once daily, which can be increased to the maximum 25 mg dose if needed for better glycemic control.

Some key points to consider when taking Jardiance include:

• Jardiance should be taken in the morning with or without food
• The medication works by helping the kidneys remove excess sugar from the bloodstream through urine, which lowers blood glucose levels
• It's essential not to exceed the 25 mg maximum daily dose, as higher doses have not been shown to provide additional benefits but may increase the risk of side effects such as urinary tract infections, genital mycotic infections, and volume depletion
• If you have kidney impairment with an eGFR less than 30 mL/min/1.73 m², Jardiance is not recommended, as stated in the guidelines for pharmacologic approaches to glycemic treatment 2
• Always take this medication exactly as prescribed by your healthcare provider and do not adjust the dose without medical supervision.

From the FDA Drug Label

The recommended dose of JARDIANCE is 10 mg once daily in the morning, taken with or without food. In patients tolerating JARDIANCE, the dose may be increased to 25 mg The maximum dose of Jardiance daily is 25 mg. 3

From the Research

Daily Dose of Jardiance (Empagliflozin)

• The maximum daily dose of Jardiance (Empagliflozin) is not explicitly stated in the provided studies, but the dosages used in the studies were 10 mg and 25 mg once daily 4, 5, 6, 7.
• The studies suggest that Empagliflozin is effective in reducing cardiovascular and kidney outcomes in patients with type 2 diabetes mellitus and established cardiovascular disease, as well as in patients with heart failure, at doses of 10 mg and 25 mg once daily 4, 5, 7.
• The safety of Empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease was assessed in a pooled analysis of placebo-controlled clinical trials, which found that the rates of serious adverse events, adverse events leading to discontinuation, and events of special interest were similar between Empagliflozin and placebo across chronic kidney disease subgroups 6.
• Another study found that the characteristics of medication-initiator cohorts in persons with chronic kidney disease and type 2 diabetes changed over time, with a decrease in prior metformin and dipeptidyl peptidase-4 inhibitor use and an increase in the number of persons with no type 2 diabetes medications other than insulin 8.

Key Findings

• Empagliflozin reduced the risk of cardiovascular death, hospitalization for heart failure, and all-cause hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease 4, 7.
• Empagliflozin improved kidney outcomes in patients with or without heart failure, including a reduction in the risk of incident or worsening nephropathy and a slower decline in estimated glomerular filtration rate 5, 7.
• The safety profile of Empagliflozin was consistent with the overall trial population, with no new safety concerns identified in patients with advanced chronic kidney disease 6.